Full upcoming catalyst calendar

Name: Bio Catalyst Calendar — source-anchored biotech/pharma catalyst dates
Creator: Bio Catalyst Calendar
License: https://www.usa.gov/government-works

602 upcoming events · verified as of 2026-06-22 · soonest first.

All · Readouts · AdComm · Recent approvals

Date	Event	Company	Drug	Official source & verification
2026-06-22 today ESTIMATED	READOUT Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) Wit Phase 2 · Waldenstrom Macroglobulinemia, Multiple Myeloma	CLRB Cellectar Biosciences, Inc.	Iopofosine I 131 single dose, Iopofosine	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-06-22 today ESTIMATED	READOUT Efficacy and Safety of Odevixibat in Children With Biliary Atresia Who Have Unde Phase 3 · Biliary Atresia	Albireo, an Ipsen Company	Odevixibat	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-06-22 today ESTIMATED	READOUT A Rollover Study to Provide Continued Treatment for Participants Previously Enro Phase 2 · Myelofibrosis, Postlung Transplant (Bronchiolitis Obliterans)	INCY INCYTE CORP	itacitinib	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-06-22 today ESTIMATED	READOUT A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab i Phase 3 · Atopic Dermatitis	AMGN AMGEN INC	Rocatinlimab	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-06-22 today ESTIMATED	READOUT A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Effectivene Phase 1/2 · Neoplasms, Colorectal, Solid Tumor	GlaxoSmithKline	GSK4418959, PD-1 inhibitor	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-06-23 in 1d ESTIMATED	READOUT Safety Study in Subjects ≥ 12 Years of Age With Hereditary Angioedema Switching Phase 4 · Hereditary Angioedema	CSL Behring	Garadacimab	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-06-26 in 4d ESTIMATED	READOUT A Study of Nipocalimab in Children Aged 2 to Less Than 18 Years With Generalized Phase 2/3 · Myasthenia Gravis	Janssen Research & Development, LL	Nipocalimab	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-06-26 in 4d ESTIMATED	READOUT A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Phase 3 · Primary Biliary Cholangitis	Ipsen	Elafibranor	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-06-26 in 4d ESTIMATED	READOUT A Study to Explore the Efficacy of JNJ-89495120 in the Treatment of Major Depres Phase 2 · Depressive Disorder, Major	Janssen Research & Development, LL	JNJ-89495120	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-06-27 in 5d ESTIMATED	READOUT Study to Evaluate Efficacy, Safety and Tolerability of HM15211(Efocipegtrutide) Phase 2 · NASH - Nonalcoholic Steatohepatitis	Hanmi Pharmaceutical Company Limit	HM15211	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-06-27 in 5d ESTIMATED	READOUT Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWA Phase 1/2 · Duchenne Muscular Dystrophy	WVE Wave Life Sciences Ltd.	WVE-N531	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-06-27 in 5d ESTIMATED	READOUT A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cance Phase 2 · Cancer Harboring BRAF Alterations, HGG	Fore Biotherapeutics	Plixorafenib	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-06-29 in 7d ESTIMATED	READOUT Study of Olaparib (MK-7339) in Combination With Pembrolizumab (MK-3475) in the T Phase 2 · Solid Tumors	Merck Sharp & Dohme LLC	Olaparib, Pembrolizumab	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-06-29 in 7d ESTIMATED	READOUT A Study to Evaluate the Treatment Response and Safety of Two Dose Regimens of Su Phase 3 · Dermatitis Atopic	SNY Sanofi	Amlitelimab	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-06-30 in 8d ESTIMATED	READOUT Phase 2 Tolerability and Effects of ALK-001 on Stargardt Disease Phase 2 · Stargardt Disease, Stargardt Macular Degeneration	Alkeus Pharmaceuticals, Inc.	ALK-001	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-06-30 in 8d ESTIMATED	READOUT Open Label Extension to Assess the Long-Term Safety and Tolerability of ZYN002 i Phase 2/3 · Fragile X Syndrome	Zynerba Pharmaceuticals, Inc.	ZYN002 - Cannabidiol Transdermal Gel	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-06-30 in 8d ESTIMATED	READOUT An Open-Label Study of Continuation Treatment With Combination Pyrimidine Nucleo Phase 2 · Thymidine Kinase 2 Deficiency	UCB BIOSCIENCES, Inc.	doxecitine and doxribtimine	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-06-30 in 8d ESTIMATED	READOUT A Study of NanO2™ Combined With Radiation and Temozolomide in Patients With Newl Phase 2 · Glioblastoma Multiforme	NuvOx LLC	NanO2TM	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-06-30 in 8d ESTIMATED	READOUT A Study of Tyrosine Kinase Inhibitor Orelabrutinib (ICP-022) in Patients With r/ Phase 1/2 · Part 1：r/r B-cell Malignancies, Part 2：B-cell Malignancies	Beijing InnoCare Pharma Tech Co.,	Orelabrutinib (ICP-022)	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-06-30 in 8d ESTIMATED	READOUT Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Maj Phase 3 · Cardiovascular Disease and Lipoprotein(a)	NVS NOVARTIS AG	TQJ230	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-06-30 in 8d ESTIMATED	READOUT Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD- Phase 1/2 · Non Small Cell Lung Cancer, Advanced Solid Tumor	OncoC4, Inc.	ONC-392, Pembrolizumab, Docetaxel	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-06-30 in 8d ESTIMATED	READOUT Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Phase 1/2 · B-cell Acute Lymphoblastic Leukemia	CLLS Cellectis S.A.	UCART22, CLLS52	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-06-30 in 8d ESTIMATED	READOUT Extension Study of P1101 After Completion of Phase 2 Study in PV Patients or Pha Phase 3 · Polycythemia Vera (PV)	PharmaEssentia Japan K.K.	P1101 (Ropeginterferon alfa-2b)	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-06-30 in 8d ESTIMATED	READOUT A Study Evaluating the Efficacy and Safety of Mosunetuzumab in Combination With Phase 3 · Relapsed or Refractory Follicular Lymphoma	Hoffmann-La Roche	Mosunetuzumab, Lenalidomide, Rituximab,	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-06-30 in 8d ESTIMATED	READOUT LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incom Phase 1/2 · Superficial Bladder Cancer, Non-muscle Invasive Bladder Cancer With Carcinoma in Situ	ENGN enGene Therapeutics Inc.	EG-70 (phase 1), EG-70 (phase 2) Master	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-06-30 in 8d ESTIMATED	READOUT A Clinical Trial Evaluating the Safety and Efficacy of a Single Subretinal Injec Phase 2/3 · X-Linked Retinitis Pigmentosa	Beacon Therapeutics	rAAV2tYF-GRK1-hRPGRco, Control	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-06-30 in 8d ESTIMATED	READOUT Evaluation of Lomecel-B™ Injection in Patients With Hypoplastic Left Heart Syndr Phase 2 · Hypoplastic Left Heart Syndrome	LGVN Longeveron Inc.	Lomecel-B medicinal signaling cells	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-06-30 in 8d ESTIMATED	READOUT A Study of 177Lu-FAP-2286 in Advanced Solid Tumors Phase 1/2 · Solid Tumor	NVS NOVARTIS AG	68Ga-FAP-2286, 177Lu-FAP-2286	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-06-30 in 8d ESTIMATED	READOUT NP-G2-044 as Monotherapy and Combination Therapy in Patients With Advanced or Me Phase 1/2 · Advanced or Metastatic Solid Tumor Malignancies	Novita Pharmaceuticals, Inc.	NP-G2-044 Monotherapy, Anti-PD-1 Therapy	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-06-30 in 8d ESTIMATED	READOUT A Study to Test the Efficacy and Safety of Staccato Alprazolam in Study Particip Phase 3 · Stereotypical Prolonged Seizures	UCB Biopharma SRL	Staccato alprazolam	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-06-30 in 8d ESTIMATED	READOUT A Beta-only IL-2 ImmunoTherapY Study Phase 1/2 · Advanced Solid Tumor, Unresectable Solid Tumor	MDNAF Medicenna Therapeutics Corp.	MDNA11, Pembrolizumab (KEYTRUDA®)	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-06-30 in 8d ESTIMATED	READOUT A Long-Term Safety Study of PTC923 in Participants With Phenylketonuria Phase 3 · Phenylketonuria	PTC PTC INC.	PTC923	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-06-30 in 8d ESTIMATED	READOUT Phase 1/2 Study of TU2218 Alone and in Combination With Checkpoint Inhibitors in Phase 1/2 · Advanced Solid Tumor	TiumBio Co., Ltd.	TU2218, Anti-PD-1 antibody	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-06-30 in 8d ESTIMATED	READOUT Safety and Immunogenicity of CRV-101 Vaccine for the Prevention of Herpes Zoster Phase 2 · Herpes Zoster, Shingles	Curevo Inc	Amezosvatein Antigen High Dose Arm A, Am	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-06-30 in 8d ESTIMATED	READOUT A Study to Evaluate the Efficacy and Safety of Serplulimab in Combination With C Phase 3 · Limited-Stage Small Cell Lung Cancer	Shanghai Henlius Biotech	HLX10, carboplatin/cisplatin-etoposide,	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-06-30 in 8d ESTIMATED	READOUT Safety and Efficacy Study of Contezolid Acefosamil and Contezolid Compared to Li Phase 3 · Diabetic Foot Infection	MicuRx	contezolid acefosamil (IV)/contezolid (P	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-06-30 in 8d ESTIMATED	READOUT Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for Phase 3 · Breast Cancer	CELC Celcuity Inc.	Gedatolisib, Palbociclib, Fulvestrant, A	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-06-30 in 8d ESTIMATED	READOUT A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1468 Phase 1/2 · Herpes Zoster	ModernaTX, Inc.	mRNA-1468, Shingrix	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-06-30 in 8d ESTIMATED	READOUT A Study of Obexelimab in Patients With Warm Autoimmune Hemolytic Anemia (SApHiAr Phase 3 · Warm Autoimmune Hemolytic Anemia	ZBIO Zenas BioPharma, Inc.	Obexelimab, Obexelimab	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-06-30 in 8d ESTIMATED	READOUT A Study of SKB264 (MK-2870; Sac-TMT) for the Treatment of Participants With Adva Phase 2 · Non-small Cell Lung Cancer	Klus Pharma Inc.	SKB264, Pembrolizumab, Carboplatin, Osim	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-06-30 in 8d ESTIMATED	READOUT A Phase 2b, Randomized, Double-blind Study of Redasemtide (S-005151) in Adult Pa Phase 2 · Acute Ischemic Stroke	SGIOF SHIONOGI & CO LTD	Redasemtide	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-06-30 in 8d ESTIMATED	READOUT OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advan Phase 3 · Breast Cancer, Advanced Breast Cancer	OLMA Olema Pharmaceuticals, Inc.	Palazestrant, Fulvestrant, Anastrozole,	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-06-30 in 8d ESTIMATED	READOUT Phase 2 Trial of HY209gel in Atopic Dermatitis Patients Phase 2 · Atopic Dermatitis, Atopic Dermatitis Eczema	Shaperon	HY209GEL Active	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-06-30 in 8d ESTIMATED	READOUT A Study of TRK-950 When Used in Combination With Ramucirumab and Paclitaxel in P Phase 2 · Gastric Adenocarcinoma, Gastric Cancer	Toray Industries, Inc	TRK-950, Ramucirumab, Paclitaxel	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-06-30 in 8d ESTIMATED	READOUT A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK), and Prel Phase 1/2 · Neoplasms	GlaxoSmithKline	GSK4524101, Niraparib	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-06-30 in 8d ESTIMATED	READOUT Indigotindisulfonate Sodium as an Aid in Determination of Ureteral Patency in Pa Phase 4 · Ureter Injury	Prove pharm	Saline Injection 0.9%, Indigotindisulfon	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-06-30 in 8d ESTIMATED	READOUT A Study of LM-24C5 For Advanced Solid Tumors Phase 1/2 · Advanced Solid Tumor	LaNova Medicines Limited	LM-24C5	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-06-30 in 8d ESTIMATED	READOUT A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab Phase 3 · Lung Cancer, Non-Small Cell	GlaxoSmithKline	Dostarlimab, Belrestotug, Pembrolizumab	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-06-30 in 8d ESTIMATED	READOUT A Study to Evaluate Solriktug in Adult Participants With Asthma Phase 2 · Asthma	Uniquity One (UNI)	NSI-8226, NSI-8226, NSI-8226	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-06-30 in 8d ESTIMATED	READOUT A Study to Evaluate Solrikitug in Participants With COPD (ZION) Phase 2 · COPD	Uniquity One (UNI)	Biological: Solrikitug low dose, Biologi	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-06-30 in 8d ESTIMATED	READOUT A Study in Patients With Mixed Dyslipidemia Phase 2 · Mixed Dyslipidemia	Shanghai Argo Biopharmaceutical Co	BW-00112	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-06-30 in 8d ESTIMATED	READOUT A Clinical Study to Evaluate DNTH103 in Adults With Multifocal Motor Neuropathy Phase 2 · Multifocal Motor Neuropathy	DNTH Dianthus Therapeutics, Inc.	Claseprubart	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-06-30 in 8d ESTIMATED	READOUT Continuation Protocol for Obstructive Sleep Apnea (OSA) Phase 3 · OSA	Apnimed	Aroxybutynin and Atomoxetine	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-06-30 in 8d ESTIMATED	READOUT A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder C Phase 1/2 · Non-Muscle Invasive Bladder Cancer	Merck Sharp & Dohme LLC	Sacituzumab tirumotecan, Rescue medicati	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-06-30 in 8d ESTIMATED	READOUT A Phase 2 in Adult Subjects With Hereditary Angioedema Phase 2 · Hereditary Angioedema (HAE)	Shanghai Argo Biopharmaceutical Co	BW-20805, BW-20805, BW-20805	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-06-30 in 8d ESTIMATED	READOUT A Phase 2 Study of YA-101 in Patients With Multiple System Atrophy Phase 2 · Multiple System Atrophy	Dasher Neuroscience Inc.	YA-101	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-06-30 in 8d ESTIMATED	READOUT An Open-label, Multicenter Study to Assess the Pharmacokinetics (PK), Safety, an Phase 4 · Primary Immunodeficiency	CSL Behring	IgPro	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-06-30 in 8d ESTIMATED	READOUT Study of Monoclonal Antibody Nirsevimab Against Respiratory Syncytial Virus (RSV Phase 4 · RSV Immunization	SNY Sanofi	Nirsevimab	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-07 (month) in 9d ESTIMATED	READOUT Study of Vimseltinib (DCC-3014) in Patients With Advanced Tumors and Tenosynovia Phase 1/2 · Advanced Malignant Neoplasm, Pigmented Villonodular Synovitis	Deciphera Pharmaceuticals, LLC	Vimseltinib	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-07 (month) in 9d ESTIMATED	READOUT Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treate Phase 2 · Non-small Cell Lung Cancer	ABBV AbbVie Inc.	Telisotuzumab vedotin	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-07 (month) in 9d ESTIMATED	READOUT Long-term Safety and Efficacy Extension Trial of Bimatoprost SR Phase 3 · Open-Angle Glaucoma, Ocular Hypertension	ABBV AbbVie Inc.	Bimatoprost SR	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-07 (month) in 9d ESTIMATED	READOUT A Study to Evaluate Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA Phase 3 · Iron Deficiency Anemia	AMAG Pharmaceuticals, Inc.	ferumoxytol, Iron sucrose	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-07-01 in 9d ESTIMATED	READOUT RAPA-501 Therapy for ALS Phase 2/3 · Amyotrophic Lateral Sclerosis	Rapa Therapeutics LLC	RAPA-501 Autologous T stem cells	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-07 (month) in 9d ESTIMATED	READOUT Study Comparing Investigational Drug HBI-8000 + Nivolumab vs. Placebo + Nivoluma Phase 3 · Unresectable or Metastatic Melanoma, Progressive Brain Metastasis	HUYABIO International, LLC.	HBI-8000 in combination with nivolumab	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-07 (month) in 9d ESTIMATED	READOUT HM15136 (Efpegerglucagon) Treatment for 8 Weeks in Subjects Aged ≥2 Years With C Phase 2 · Congenital Hyperinsulinism	Hanmi Pharmaceutical Company Limit	HM15136	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-07 (month) in 9d ESTIMATED	READOUT A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patien Phase 3 · Gastro-enteropancreatic Neuroendocrine Tumor	Camurus AB	CAM2029, Octreotide LAR, Lanreotide ATG	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-07 (month) in 9d ESTIMATED	READOUT Study of Combination Therapy of D07001-Softgel Capsules and Xeloda/TS-1 in Subje Phase 2/3 · Biliary Tract Cancer	InnoPharmax Inc.	D07001-softgel capsules + Xeloda (or TS-	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-07 (month) in 9d ESTIMATED	READOUT Rho Kinase Inhibitor in Amyotrophic Lateral Sclerosis (REAL) Phase 2 · Amyotrophic Lateral Sclerosis	Woolsey Pharmaceuticals	Fasudil (WP-0512), Fasudil (WP-0512)	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-07-01 in 9d ESTIMATED	READOUT Modi-1 Moditope in Breast, Head and Neck, Ovarian, or Renal Cancer Phase 1/2 · Triple Negative Breast Cancer, Renal Cell Cancer	Scancell Ltd	Modi-1 Moditope, Pembrolizumab, MicronJe	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-07 (month) in 9d ESTIMATED	READOUT An Open-label Study of Povetacicept in Participants With Autoimmune Cytopenias Phase 1/2 · Immune Thrombocytopenia, Idiopathic Thrombocytopenic Purpura	Alpine Immune Sciences, Inc.	povetacicept	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-07 (month) in 9d ESTIMATED	READOUT Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitin Phase 3 · Rheumatoid Arthritis	ABBV AbbVie Inc.	Upadacitinib, Adalimumab, Upadacitinib M	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-07 (month) in 9d ESTIMATED	READOUT Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Phase 1/2 · NSCLC, HNSCC	CJ Bioscience, Inc.	CJRB-101, Pembrolizumab injection	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-07-01 in 9d ESTIMATED	READOUT Phase 2 Placebo-Controlled Study to Assess the Safety and Efficacy of ESK-001 in Phase 2 · SLE	ALMS ALUMIS INC.	Envudeucitinib	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-07 (month) in 9d ESTIMATED	READOUT Safety, PK, and Preliminary Efficacy of MBRC-101 in Advanced Refractory Solid Tu Phase 1/2 · Cancer	MBrace Therapeutics	Antibody-Drug Conjugate	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-07-01 in 9d ESTIMATED	READOUT A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination Wit Phase 2 · Hepatocellular Carcinoma (HCC)	AZN ASTRAZENECA PLC	Durvalumab, Bevacizumab, Transarterial R	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-07 (month) in 9d ESTIMATED	READOUT Study on Efficacy and Safety of Givinostat Versus Hydroxyurea in Patients With P Phase 3 · Polycythemia Vera	Italfarmaco	Givinostat, Hydroxyurea	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-07 (month) in 9d ESTIMATED	READOUT Study of Lenacapavir and Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) in Phase 2 · Pre-Exposure Prophylaxis of HIV Infection	GILD GILEAD SCIENCES, INC.	Lenacapavir Tablet, Lenacapavir Injectio	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-07 (month) in 9d ESTIMATED	READOUT Trial to Visualize the Ureters With Nizaracianine Triflutate in Adults Undergoin Phase 2/3 · Injury of Ureter During Surgery (Disorder)	Curadel Surgical Innovations, Inc.	Nizaracianine Triflutate	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-07-01 in 9d ESTIMATED	READOUT To Evaluate the Safety and Efficacy of MANP in Subjects With Difficult to Contro Phase 2 · Difficult to Control Hypertension	E-Star BioTech, LLC	MANP	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-07 (month) in 9d ESTIMATED	READOUT A Study of Pitolisant in Patients With Prader-Willi Syndrome Phase 3 · Prader-Willi Syndrome	Harmony Biosciences Management, In	Pitolisant tablet	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-07 (month) in 9d ESTIMATED	READOUT A Study of Auxora in Patients With AKI and Injurious Lung "Crosstalk" Phase 2 · Acute Kidney Injury	CALC CalciMedica, Inc.	Auxora	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-07-01 in 9d ESTIMATED	READOUT ProAgio in Combination With Gemcitabine in Patients With Metastatic Triple Negat Phase 1/2 · Triple Negative Breast Cancer	ProDa BioTech, LLC	ProAgio Dose Levels (DL) 1,2,3,4, ProAgi	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-07 (month) in 9d ESTIMATED	READOUT Confirmatory Study of Topical HyBryte™ vs. Placebo for the Treatment of CTCL Phase 3 · CTCL/ Mycosis Fungoides, CTCL	SNGX SOLIGENIX, INC.	Hypericin	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-07 (month) in 9d ESTIMATED	READOUT A Study to Evaluate the Efficacy and Safety of Sotagliflozin in Symptomatic Obst Phase 3 · Obstructive Cardiomyopathy, Hypertrophic, Non-obstructive Hypertrophic Cardiomyopathy	LXRX LEXICON PHARMACEUTICALS, INC	Sotagliflozin	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-07 (month) in 9d ESTIMATED	READOUT 4-Week, Multi-center Dose-Ranging Study for the IBS-C in Pts. 6 to <12 Yrs Phase 2 · Irritable Bowel Syndrome With Constipation (IBS-C)	ARDX ARDELYX, INC.	Tenapanor	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-07 (month) in 9d ESTIMATED	READOUT A Study on TLC590 for Managing Postsurgical Pain Phase 2 · Postsurgical Pain Management	TLC Biopharmaceuticals, Inc.	TLC590, TLC590, TLC590, TLC590	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-07 (month) in 9d ESTIMATED	READOUT Phase 3 Efficacy and Safety Study of GTX-102 in Pediatric Subjects With Angelman Phase 3 · Angelman Syndrome	RARE Ultragenyx Pharmaceutical In	GTX-102	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-07 (month) in 9d ESTIMATED	READOUT A Study to Evaluate the Efficacy and Safety of Combination Therapy of BRII-179, Phase 2 · Chronic Hepatitis B Virus (HBV) Infection	Brii Biosciences Limited	BRII-179, BRII-835 (VIR-2218), PEG-IFNα	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-07 (month) in 9d ESTIMATED	READOUT A Study to Assess Adverse Events and Change in Disease Activity in Participants Phase 2 · Advanced High-Grade Epithelial Ovarian Cancer, Primary Peritoneal Cancer	ABBV AbbVie Inc.	Mirvetuximab Soravtansine	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-07 (month) in 9d ESTIMATED	READOUT A Phase 3 Trial of DT120 for Generalized Anxiety Disorder (Voyage) Phase 3 · Generalized Anxiety Disorder	DFTX Definium Therapeutics, Inc.	DT120	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-07 (month) in 9d ESTIMATED	READOUT Efficacy and Safety Study of Halneuron in the Treatment of Chemotherapy-Induced Phase 2 · Chemotherapy Induced Neuropathic Pain, Chemotherapy Induced Pain Neuropathy	DWTX Dogwood Therapeutics, Inc.	Halneuron, Halneuron (Open Label Extensi	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-07 (month) in 9d ESTIMATED	READOUT A Study of ONO-2020 in Participants With Mild to Moderate Alzheimer's Disease Phase 2 · Alzheimer Disease	Ono Pharmaceutical Co., Ltd.	ONO-2020	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-07 (month) in 9d ESTIMATED	READOUT A Clinical Trial Evaluating the Efficacy and Safety of Leflutrozole on Testicula Phase 2 · Semen Quality	ReproNovo Aps	Leflutrozole, Dose 1, Leflutrozole, Dose	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-07 (month) in 9d ESTIMATED	READOUT Study of MAR001 in Adults With Elevated Triglycerides and Remnant Cholesterol Phase 2 · Hypertriglyceridemia	Marea Therapeutics	MAR001	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-07 (month) in 9d ESTIMATED	READOUT Proof-of-concept Study to Evaluate the Safety, Tolerability, Pharmacodynamics, a Phase 2 · Cystic Fibrosis (CF)	SION Sionna Therapeutics, Inc.	SION-719	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-07 (month) in 9d ESTIMATED	READOUT Safety and Efficacy of Boric Acid Inserts for Treatment of Vulvovaginal Candidia Phase 3 · Vulvovaginal Candidiases, Vulvovaginal Candidiasis, Genital	pH-D Feminine Health LLC	Boric acid	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-07 (month) in 9d ESTIMATED	READOUT A Study to Examine Anktiva for the Treatment of COVID-19. Phase 2 · Long COVID, Long COVID Syndrome	IBRX ImmunityBio, Inc.	Anktiva	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-07 (month) in 9d ESTIMATED	READOUT Phase 2b Study of EVO756 in Adults With Atopic Dermatitis Phase 2 · Atoptic Dermatitis	EVMN Evommune, Inc.	EVO756, EVO756, EVO756	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-07 (month) in 9d ESTIMATED	READOUT A Safety, Tolerability and Pharmacokinetics Study of VRDN-003 in Participants Wi Phase 3 · Thyroid Eye Disease	VRDN Viridian Therapeutics, Inc.D	VRDN-003, Autoinjector	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-07 (month) in 9d ESTIMATED	READOUT A Mechanistic Study of MAR001 in Adults With Elevated Triglycerides and Remnant Phase 2 · Hypertriglyceridemia	Marea Therapeutics	MAR001	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-07 (month) in 9d ESTIMATED	READOUT A Study Comparing the Clinical Benefit of Finerenone Versus a Fixed Dose Combina Phase 3 · Hypertension (HTN)	Sarfez Pharmaceuticals, Inc.	Combination Product: FDC of spironolacto	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-07 (month) in 9d ESTIMATED	READOUT A Trial to Investigate the Safety and Efficacy of Intra-articular 4P004 Injectio Phase 2 · Knee Osteoarthritis, Synovitis of Knee	4Moving Biotech	4P004	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-07 (month) in 9d ESTIMATED	READOUT A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study With Phase 2 · Cutaneous Lupus Erythematosus (CLE), Systemic Lupus Erythematosus	Ventus Therapeutics U.S., Inc.	VENT-03	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-07 (month) in 9d ESTIMATED	READOUT A Study of Weekly Oral Ecnoglutide (VRB-101) in Participants Who Have Obesity or Phase 2 · Obesity, Overweight	Verdiva Bio Dev Limited	VRB-101	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-07-01 in 9d ESTIMATED	READOUT Study of QLS-111-FDC in Open-Angle Glaucoma or Ocular Hypertension Phase 2/3 · OAG - Open-Angle Glaucoma, OHT - Ocular Hypertension	Qlaris Bio, Inc.	QLS-111-FDC, Latanoprost (0.005%)	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-07 (month) in 9d ESTIMATED	READOUT Clinical Investigation of Oral Malodor for Max Fresh Toothpaste Containing Zinc Phase 3 · Oral Malodor	CL COLGATE PALMOLIVE CO	Max Fresh Toothpaste, Colgate Cavity Pro	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-07 (month) in 9d ESTIMATED	READOUT A Phase 2 Safety, Tolerability, PK, and Efficacy Study of CS-1103 Following Fent Phase 2 · Fentanyl Overdose, Fentanyl Poisoning	Clear Scientific, Inc.	Naloxone Hydrochloride, Fentanyl, Steril	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-07-03 in 11d ESTIMATED	READOUT Study to Evaluate Safety, Tolerability and Drug Levels of BMS-986435/MYK-224 in Phase 2 · Heart Failure	BMY BRISTOL MYERS SQUIBB CO	BMS-986435	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-07-03 in 11d ESTIMATED	READOUT A Ph1b/2 Study of Axatilimab Monotherapy in Chinese Participants With Recurrent Phase 1/2 · Chronic Graft-versus-host-disease	INCY INCYTE CORP	INCA034176	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-07-06 in 14d ESTIMATED	READOUT A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Adult Pa Phase 2 · B-cell Non-Hodgkin Lymphoma (B-NHL)	REGN REGENERON PHARMACEUTICALS, I	Odronextamab	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-07-06 in 14d ESTIMATED	READOUT Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuz Phase 3 · Breast Cancer; HER2-positive; Metastatic	AZN ASTRAZENECA PLC	Trastuzumab deruxtecan, Taxane, Pertuzum	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-07-07 in 15d ESTIMATED	READOUT To Evaluate the Efficacy/Safety of Osimertinib Prior to CRT and Maintenance of i Phase 2 · Lung Cancer	AZN ASTRAZENECA PLC	Osimertinib, Cisplatin or Carboplatin; P	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-07-09 in 17d ESTIMATED	READOUT A Study of Nivolumab in Combination With Ipilimumab in Participants With Advance Phase 3 · Hepatocellular Carcinoma	BMY BRISTOL MYERS SQUIBB CO	Nivolumab, Ipilimumab, Sorafenib, lenvat	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-07-09 in 17d ESTIMATED	READOUT A Study to Evaluate Mavacamten Impact on Myocardial Structure in Participants Wi Phase 4 · Cardiomyopathy, Hypertrophic	BMY BRISTOL MYERS SQUIBB CO	Mavacamten	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-07-10 in 18d ESTIMATED	READOUT Efficacy and Safety of Frexalimab (SAR441344) in the Treatment of Systemic Lupus Phase 2 · Systemic Lupus Erythematosus	SNY Sanofi	SAR441344 IV, SAR441344 SC	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-07-10 in 18d ESTIMATED	READOUT A Double-Blind, Randomized, Vehicle-Controlled Phase 2 Study to Assess the Effic Phase 2 · Eczema Atopic Dermatitis, Eczema	TTRX Turn Therapeutics Inc.	GX-03, Vehicle	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-07-13 in 21d ESTIMATED	READOUT A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevromet Phase 3 · Metastatic Castrate Resistant Prostate Cancer (mCRPC)	PFE PFIZER INC	PF-06821497, Docetaxel, Enzalutamide	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-07-13 in 21d ESTIMATED	READOUT A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children and A Phase 3 · Atopic Dermatitis	INCY INCYTE CORP	Ruxolitinib, Vehicle Cream	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-07-14 in 22d ESTIMATED	READOUT Efficacy and Safety of Tezepelumab in Patients With Eosinophilic Esophagitis Phase 3 · Eosinophilic Esophagitis	AZN ASTRAZENECA PLC	Tezepelumab, Tezepelumab	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-07-14 in 22d ESTIMATED	READOUT A Study of the Safety of Mibavademab in Pediatric and Adult Participants Switchi Phase 3 · Generalized Lipodystrophy	REGN REGENERON PHARMACEUTICALS, I	mibavademab	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-07-15 in 23d ESTIMATED	READOUT Corneal Crosslinking for Treatment of Corneal Neovascularization Phase 2/3 · Corneal Neovascularization	Price Vision Group	30 minute photoactivation of riboflavin	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-07-15 in 23d ESTIMATED	READOUT Evaluation of PK, PD, Efficacy, Safety, and Immunogenicity of IV Ravulizumab in Phase 3 · Generalized Myasthenia Gravis, gMG	Alexion Pharmaceuticals, Inc.	Ravulizumab	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-07-15 in 23d ESTIMATED	READOUT A Study of the Efficacy and Safety of SP-624 in the Treatment of Adults With Maj Phase 2 · Major Depressive Disorder	Sirtsei Pharmaceuticals, Inc.	SP-624	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-07-15 in 23d ESTIMATED	READOUT Namodenoson Treatment of Advanced Pancreatic Cancer Phase 2 · Pancreatic Adenocarcinoma, Pancreatic Cancer	CANF Can-Fite BioPharma Ltd.	Namodenoson 25mg	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-07-15 in 23d ESTIMATED	READOUT Safety and Efficacy of IMM01-STEM Against Placebo on Muscle Performance in Senio Phase 2 · Muscle Performance, Sarcopenic Obesity	Immunis, Inc.	IMM01-STEM, IMM01-STEM alternating with	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-07-16 in 24d ESTIMATED	READOUT A Study of TAK-360 in Adults With Idiopathic Hypersomnia Phase 2 · Idiopathic Hypersomnia	TAK TAKEDA PHARMACEUTICAL CO LTD	TAK-360	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-07-17 in 25d ESTIMATED	READOUT Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participan Phase 1/2 · Carcinoma, Renal Cell	Merck Sharp & Dohme LLC	Pembrolizumab, Favezelimab/Pembrolizumab	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-07-17 in 25d ESTIMATED	READOUT Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participan Phase 1/2 · Carcinoma, Renal Cell	Merck Sharp & Dohme LLC	Pembrolizumab, MK-4830, Belzutifan, Lenv	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-07-17 in 25d ESTIMATED	READOUT A Dose Finding Study With an Anti-TSLP Antibody (GSK5784283) in Adults Aged 18 t Phase 2 · Asthma	GlaxoSmithKline	GSK5784283	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-07-18 in 26d ESTIMATED	READOUT A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethason Phase 3 · Relapsed or Refractory Multiple Myeloma	BMY BRISTOL MYERS SQUIBB CO	Mezigdomide, Carfilzomib, Dexamethasone	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-07-21 in 29d ESTIMATED	READOUT Study to Evaluate the Safety and Efficacy of Daily Subcutaneous Metreleptin Trea Phase 3 · Partial Lipodystrophy	Chiesi Farmaceutici S.p.A.	metreleptin	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-07-21 in 29d ESTIMATED	READOUT A Study of Belzutifan (MK-6482) in Combination With Palbociclib Versus Belzutifa Phase 1/2 · Renal Cell Carcinoma	Merck Sharp & Dohme LLC	Belzutifan, Palbociclib	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-07-22 in 30d ESTIMATED	READOUT A Study to Evaluate INCB099280 in Participants With Select Solid Tumors Who Are Phase 2 · Advanced Solid Tumor	INCY INCYTE CORP	INCB099280	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-07-22 in 30d ESTIMATED	READOUT A Study to Assess the Efficacy and Safety of Afimkibart (RO7790121) in Participa Phase 2 · Atopic Dermatitis	Hoffmann-La Roche	Afimkibart	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-07-23 in 1mo ESTIMATED	READOUT Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants Wi Phase 3 · Relapsing Multiple Sclerosis	NVS NOVARTIS AG	Remibrutinib, Teriflunomide	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-07-23 in 1mo ESTIMATED	READOUT Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants Wi Phase 3 · Relapsing Multiple Sclerosis	NVS NOVARTIS AG	Remibrutinib, Teriflunomide	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-07-23 in 1mo ESTIMATED	READOUT A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Heal Phase 3 · SARS-CoV-2 Virus, Severe Acute Respiratory Syndrome Coronavirus 2	BNTX BioNTech SE	Bivalent BNT162b2 (original/Omicron BA.4	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-07-23 in 1mo ESTIMATED	READOUT A Study to Test Whether Spesolimab Helps People With Generalized Pustular Psoria Phase 4 · Generalized Pustular Psoriasis	Boehringer Ingelheim	Spesolimab	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-07-23 in 1mo CONFIRMED	ADCOM Pharmacy Compounding Advisory Committee Pharmacy Compounding Advisory Committee	Pharmacy Compounding Advisory Comm	AdComm review	Federal Register (FDA notice) ↗ ✓ Source-checked 2026-06-22 Scheduled FDA meeting date
2026-07-24 in 1mo ESTIMATED	READOUT A Study to Evaluate the Efficacy and Safety of JNJ-77242113 (Icotrokinra) in Bio Phase 3 · Arthritis, Psoriatic	Janssen Research & Development, LL	Icotrokinra, Active reference comparator	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-07-25 in 1mo ESTIMATED	READOUT Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-98 Phase 3 · Psoriasis	BMY BRISTOL MYERS SQUIBB CO	BMS-986165	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-07-28 in 1mo ESTIMATED	READOUT A Study to Test the Long-term Treatment of Bimekizumab in Study Participants Wit Phase 3 · Hidradenitis Suppurativa	UCB Biopharma SRL	Bimekizumab	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-07-28 in 1mo ESTIMATED	READOUT Study of LP-184 in Patients With Advanced Solid Tumors Phase 1/2 · Advanced Solid Tumor, Metastatic Solid Tumor	LTRN Lantern Pharma Inc.	LP-184, Olaparib, Nivolumab & Ipilimumab	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-07-30 in 1mo ESTIMATED	READOUT Open-Label Study of 18F-mFBG for Imaging Neuroblastoma Phase 3 · Neuroblastoma	Innervate Radiopharmaceuticals LLC	18F-MFBG	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-07-30 in 1mo ESTIMATED	READOUT EPIC-Peds: A Study to Learn About the Study Medicine Called PF-07321332 (Nirmatr Phase 3 · COVID-19	PFE PFIZER INC	nirmatrelvir, ritonavir	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-07-30 in 1mo ESTIMATED	READOUT A First-in-Human, Open-Label, Dose-Escalation Study to Evaluate the Safety and T Phase 1/2 · Neuronal Ceroid Lipofuscinosis Type 2	Tern Therapeutics, LLC	TTX-381	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-07-30 in 1mo ESTIMATED	READOUT Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL Phase 2 · Advanced Cancer, Metastatic Cancer	Mirati Therapeutics Inc.	Adagrasib	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-07-30 in 1mo ESTIMATED	READOUT A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Target Phase 3 · Respiratory Syncytial Virus	ModernaTX, Inc.	mRNA-1345	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-07-30 in 1mo ESTIMATED	READOUT A Phase 2 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of YL202 i Phase 2 · Locally Advanced or Metastatic Breast Cancer	MediLink Therapeutics (Suzhou) Co.	YL202 should be intravenously infused	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-07-30 in 1mo ESTIMATED	READOUT A Study to Evaluate INCB177054 in Participants With Select Advanced or Metastati Phase 1/2 · Solid Tumors, Advanced Solid Tumors	INCY INCYTE CORP	INCB177054, Retifanlimab	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-07-30 in 1mo ESTIMATED	READOUT Clinical Study of QRX003 Lotion in Subjects With Netherton Syndrome Phase 2/3 · Netherton Syndrome	QNRX Quoin Pharmaceuticals, Ltd.	QRX003, 4% Lotion	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-07-31 in 1mo ESTIMATED	READOUT A Clinical Efficacy and Safety Study of OHB-607 in Preventing Bronchopulmonary D Phase 2 · Bronchopulmonary Dysplasia, Chronic Lung Disease of Prematurity	OHB Neonatology Ltd.	OHB-607	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-07-31 in 1mo ESTIMATED	READOUT Safety and Pharmacokinetics of ODM-208 in Patients With Metastatic Castration-re Phase 1/2 · Prostate Cancer Metastatic	ORN Orion Group Holdings Inc	ODM-208, Midazolam	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-07-31 in 1mo ESTIMATED	READOUT Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calm Phase 3 · High-risk Non-muscle Invasive Bladder Cancer	Merck Sharp & Dohme LLC	Pembrolizumab, BCG	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-07-31 in 1mo ESTIMATED	READOUT Artesunate Vaginal Inserts for the Treatment of Cervical Intraepithelial Neoplas Phase 2 · CIN 2/3, HPV Infection	Frantz Viral Therapeutics, LLC	Artesunate vaginal insert	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-07-31 in 1mo ESTIMATED	READOUT Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Ex Phase 1/2 · Advanced Solid Tumor Historically Known for High EphA2 Expression, Urothelial Cancer	BicycleTx Limited	BT5528, Nivolumab	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-07-31 in 1mo ESTIMATED	READOUT Study to Assess the Safety, Tolerability, and Efficacy of IDX-1197 in Combinatio Phase 1/2 · Gastric Cancer	Idience Co., Ltd.	IDX-1197+XELOX, IDX-1197+Irinotecan	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-07-31 in 1mo ESTIMATED	READOUT A Study to Learn About the Long-Term Safety of Higher Doses of Nusinersen (BIIB0 Phase 3 · Muscular Atrophy, Spinal	BIIB BIOGEN INC.	Nusinersen	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-07-31 in 1mo ESTIMATED	READOUT A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizum Phase 3 · Gastric Neoplasms, Gastroesophageal Adenocarcinoma	JAZZ Jazz Pharmaceuticals plc	Zanidatamab, Tislelizumab, Trastuzumab,	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-07-31 in 1mo ESTIMATED	READOUT A Study to Explore Signs, Symptoms, and Biomarkers in Dry Eye Disease Participan Phase 4 · Dry Eye Disease	Hoffmann-La Roche	Vevye®, Xiidra®	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-07-31 in 1mo ESTIMATED	READOUT Safety, Tolerability, and Efficacy of NVG-2089 in Participants With CIDP Phase 2 · Chronic Inflammatory Demyelinating Polyneuropathy	Nuvig Therapeutics, Inc.	NVG-2089	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-07-31 in 1mo ESTIMATED	READOUT A Study of BGM0504 in Participants With Type 2 Diabetes in Indonesia Phase 3 · Type 2 Diabetes (T2DM)	BrightGene Bio-Medical Technology	BGM0504, BGM0504, Semaglutide	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-07-31 in 1mo ESTIMATED	READOUT A Study to Evaluate the Immune Response and Safety of an Influenza Vaccine in Ad Phase 2 · Influenza, Human	GlaxoSmithKline	Flu mRNA (Formulation B1), Flu mRNA (For	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-07-31 in 1mo ESTIMATED	READOUT A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in C Phase 3 · COVID-19, SARS-COV-2 Infection	BNTX BioNTech SE	BNT162b2 (2025/2026 formulation)	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-07-31 in 1mo ESTIMATED	READOUT A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years Phase 3 · COVID-19, SARS-COV-2 Infection	BNTX BioNTech SE	BNT162b2 Vaccine	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-07-31 in 1mo ESTIMATED	READOUT Efficacy of Placental Membrane Dressings in Accelerating Diabetic Foot Healing Phase 4 · Diabete Mellitus, Foot Ulcer Chronic	BioXTek	Placental Membrane	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-08 (month) in 1mo ESTIMATED	READOUT CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA- Phase 1/2 · Relapsed Hematologic Malignancy, Refractory Hematologic Malignancy	CRIS CURIS INC	Emavusertib, Ibrutinib	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-08 (month) in 1mo ESTIMATED	READOUT A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexameth Phase 3 · Multiple Myeloma	ABBV AbbVie Inc.	Pomalidomide, Dexamethasone, Venetoclax	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-08 (month) in 1mo ESTIMATED	READOUT Cenobamate Open-Label Extension Study for YKP3089C025 Phase 3 · Primary Generalized Tonic Clonic Seizures in the Setting of Idiopathic Generalized Epilepsy	SK Life Science, Inc.	Cenobamate	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-08 (month) in 1mo ESTIMATED	READOUT A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies Phase 1/2 · Advanced Malignant Neoplasm, Breast Cancer	AtlasMedx, Incorporated	AMXI-5001:Dose Escalation Phase I, AMXI-	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-08 (month) in 1mo ESTIMATED	READOUT RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants W Phase 2 · Neovascular Age-Related Macular Degeneration (nAMD)	ABBV AbbVie Inc.	Ranibizumab, ABBV-RGX-314 Dose 1, ABBV-R	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-08-01 in 1mo ESTIMATED	READOUT Study of Zifibancimig in Participants With Neovascular Age-related Macular Degen Phase 1/2 · Macular Degeneration	Hoffmann-La Roche	Zifibancimig, Ranibizumab, Port Delivery	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-08-01 in 1mo ESTIMATED	READOUT Perivenous Dexamethasone Therapy: Examining Reduction of Inflammation After Thro Phase 2 · Thrombosis, Deep Vein, Iliofemoral; Thrombosis	Mercator MedSystems, Inc.	Perivascular dexamethasone, Perivascular	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-08 (month) in 1mo ESTIMATED	READOUT Study BT7480-100 in Patients With Advanced Malignancies Associated With Nectin-4 Phase 1/2 · Advanced Solid Tumor	BicycleTx Limited	BT7480, Nivolumab	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-08 (month) in 1mo ESTIMATED	READOUT AB8939 in Patients With Relapsed/Refractory Acute Myeloid Leukemia Phase 1/2 · Acute Myeloid Leukemia Refractory, Acute Myeloid Leukemia, in Relapse	SLBT SL Science Holding Ltd	AB8939, Venetoclax	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-08 (month) in 1mo ESTIMATED	READOUT CFI-402257, a Potent and Selective TTK Inhibitor, in Solid Tumors and With Fulve Phase 1/2 · Advanced Solid Tumor, Breast Cancer	Treadwell Therapeutics, Inc	CFI-402257, Fulvestrant	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-08 (month) in 1mo ESTIMATED	READOUT Study of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS) Phase 1/2 · Low Risk Myelodysplastic Syndromes	RIGL RIGEL PHARMACEUTICALS INC	R906289 Monosodium (R289 Na)	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-08 (month) in 1mo ESTIMATED	READOUT JAB-2485 Activity in Adult Patients With Advanced Solid Tumors Phase 1/2 · Solid Tumors, ER+ Breast Cancer	Jacobio Pharmaceuticals Co., Ltd.	JAB-2485 (Aurora A inhibitor), JAB-2485	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-08 (month) in 1mo ESTIMATED	READOUT Clinical Trial on Agitation in Alzheimer's Dementia Phase 2 · Alzheimer Disease, Agitation,Psychomotor	IGC IGC Pharma, Inc.	IGC-AD1-Active, IGC-AD1-Placebo	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-08 (month) in 1mo ESTIMATED	READOUT Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p5 Phase 3 · Endometrial Cancer	KPTI Karyopharm Therapeutics Inc.	Selinexor, Matching Placebo for selinexo	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-08-01 in 1mo ESTIMATED	READOUT A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytome Phase 2 · Cytomegalovirus Infection	ModernaTX, Inc.	mRNA-1647	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-08-01 in 1mo ESTIMATED	READOUT First-in-Human Study of BBT-207 in Advanced Non-Small Cell Lung Cancer Harboring Phase 1/2 · EGFR Mutant Advanced Non-Small Cell Lung Cancer	Bridge Biotherapeutics, Inc.	BBT-207	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-08 (month) in 1mo ESTIMATED	READOUT Nuwiq for Perioperative Management Of Patients With Haemophilia A on Emicizumab Phase 4 · Severe Hemophilia A	Octapharma	Nuwiq	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-08 (month) in 1mo ESTIMATED	READOUT KYSA-1: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Thera Phase 1/2 · Lupus Nephritis, Lupus Nephritis - World Health Organization (WHO) Class III	KYTX Kyverna Therapeutics, Inc.	KYV-101 anti-CD19 CAR-T cell therapy, St	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-08 (month) in 1mo ESTIMATED	READOUT Efficacy and Safety of Patidegib Gel 2% for Preventing Basal Cell Carcinomas on Phase 3 · Gorlin Syndrome	SLGL Sol-Gel Technologies Ltd.	Patidegib Topical Gel, Patidegib Topical	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-08-01 in 1mo ESTIMATED	READOUT A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participant Phase 3 · Ulcerative Colitis	Merck Sharp & Dohme LLC	IV Tulisokibart, IV Placebo, SC Tulisoki	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-08-01 in 1mo ESTIMATED	READOUT A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combinati Phase 1/2 · Cancer, Tumor, Solid	OncoResponse, Inc.	OR502, Cemiplimab	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-08 (month) in 1mo ESTIMATED	READOUT Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type Phase 3 · Diabetes Mellitus, Type 2	LLY ELI LILLY & Co	Retatrutide, Semaglutide	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-08 (month) in 1mo ESTIMATED	READOUT A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Der Phase 3 · Atopic Dermatitis	ABBV AbbVie Inc.	Upadacitinib 15mg Dose, Dupilumab 300mg	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-08 (month) in 1mo ESTIMATED	READOUT Global Study of Del-desiran for the Treatment of DM1 Phase 3 · DM1, Myotonic Dystrophy	Avidity Biosciences, Inc.	AOC 1001 (del-desiran)	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-08-01 in 1mo ESTIMATED	READOUT Interventional Study of Vosoritide for the Treatment of Children With Hypochondr Phase 3 · Hypochondroplasia	BMRN BIOMARIN PHARMACEUTICAL INC	Vosoritide	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-08-01 in 1mo ESTIMATED	READOUT A Study to Assess the Efficacy, Safety and Tolerability of VLS-01 Buccal Film, C Phase 2 · Treatment Resistant Depression	atai Therapeutics, Inc.	VLS-01-203 BU, VLS-01-BU Placebo	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-08 (month) in 1mo ESTIMATED	READOUT Safety and Efficacy of VDPHL01 in Males and Females With AGA Phase 2 · Androgenetic Alopecia, AGA	MANE Veradermics, Inc	VDPHL01	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-08 (month) in 1mo ESTIMATED	READOUT To Evaluate the Efficacy of CVN424 in Parkinson's Disease Participants With Moto Phase 3 · Parkinson Disease	Cerevance	CVN424 75 mg, CVN424 150 mg	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-08 (month) in 1mo ESTIMATED	READOUT A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafus Phase 3 · Wet Age-related Macular Degeneration	KOD Kodiak Sciences Inc.	Tarcocimab tedromer, Tabirafusp tedromer	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-08 (month) in 1mo ESTIMATED	READOUT "A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressiv Phase 3 · Major Depressive Disorder	Cybin IRL Limited	CYB003, Psychological Support	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-08 (month) in 1mo ESTIMATED	READOUT A Phase 2 Study to Evaluate JCXH-105, an srRNA-based Herpes Zoster Vaccine Phase 2 · Herpes Zoster (HZ), Infectious Diseases	Immorna Biotherapeutics, Inc.	JCXH-105, Shingrix	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-08 (month) in 1mo ESTIMATED	READOUT PF614 Analgesic Activity in Acute Postoperative Pain (PF614-301) Phase 3 · Postoperative Pain, Acute	ENSC Ensysce Biosciences, Inc.	PF614 capsule	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-08 (month) in 1mo ESTIMATED	READOUT ALTO-100 in Bipolar Disorder With Depression (BD-D) Phase 2 · Bipolar Disorder I or II With a Major Depressive Episode	ANRO Alto Neuroscience, Inc.	ALTO-100	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-08 (month) in 1mo ESTIMATED	READOUT A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration Phase 3 · Wet Age Related Macular Degeneration, wAMD	EYPT EyePoint, Inc.	EYP-1901, Aflibercept (2.0 mg)	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-08 (month) in 1mo ESTIMATED	READOUT Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angi Phase 3 · Hereditary Angioedema (HAE)	Pharvaris Netherlands B.V.	Deucrictibant	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-08 (month) in 1mo ESTIMATED	READOUT Study of Novel Treatment Combination Therapies in Participants With Head and Nec Phase 2 · Head and Neck Squamous Cell Carcinoma	GILD GILEAD SCIENCES, INC.	Domvanalimab, Zimberelimab, Paclitaxel,	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-08 (month) in 1mo ESTIMATED	READOUT A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder Phase 3 · Major Depressive Disorder	XENE Xenon Pharmaceuticals Inc.	Azetukalner	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-08 (month) in 1mo ESTIMATED	READOUT Rapid Drug Desensitization Study in Adults Experiencing Hypersensitivity Reactio Phase 4 · Phenylketonuria, PKU	BMRN BIOMARIN PHARMACEUTICAL INC	RDD to Palynziq	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-08 (month) in 1mo ESTIMATED	READOUT A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Panorama) Phase 3 · Generalized Anxiety Disorder	DFTX Definium Therapeutics, Inc.	DT120	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-08 (month) in 1mo ESTIMATED	READOUT A Study to Evaluate Mazdutide Compared With Placebo in Participants With Alcohol Phase 2 · Alcohol Use Disorder	LLY ELI LILLY & Co	Mazdutide	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-08 (month) in 1mo ESTIMATED	READOUT NE3107 in Adults With Neurological Symptoms of Long COVID Phase 2 · Long COVID	BIVI BIOVIE INC.	NE3107	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-08 (month) in 1mo ESTIMATED	READOUT Safety and Efficacy of iDose® TR With Cataract Surgery vs. Cataract Surgery Alon Phase 4 · Glaucoma, Open-angle, Ocular Hypertension (OHT)	GKOS GLAUKOS Corp	iDose TR (travoprost intracameral implan	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-08 (month) in 1mo ESTIMATED	READOUT A Phase 1/2 Study to Evaluate the Safety, PK and Efficacy of TNP-2092 Administer Phase 1/2 · Periprosthetic Joint Infection (PJI)	TenNor Therapeutics Inc.	TNP-2092 for injection, Vancomycin Hydro	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-08 (month) in 1mo ESTIMATED	READOUT To Evaluate the Efficacy of Three Times Weekly (TIW) Vadadustat Compared to Stan Phase 3 · Anemia of Chronic Kidney Disease	AKBA Akebia Therapeutics, Inc.	Erythropoiesis-Stimulating Agent (ESA),	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-08 (month) in 1mo ESTIMATED	READOUT Relacorilant in Combination With Different Treatment Regimens in Patients With G Phase 2 · Ovarian Cancer, Fallopian Tube Cancer	CORT CORCEPT THERAPEUTICS INC	Relacorilant 150 mg once daily (QD), Nab	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-08 (month) in 1mo ESTIMATED	READOUT A Study to Evaluate the Clinical Outcomes of Efgartigimod PH20 SC in Adults With Phase 4 · New Onset Generalized Myasthenia Gravis (gMG)	ARGX ARGENX SE	Efgartigimod PH20 SC	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-08 (month) in 1mo ESTIMATED	READOUT ATI-045 Versus Placebo in Patients With Moderate-to-Severe Atopic Dermatitis Phase 2 · Atopic Dermatitis, Atopic	ACRS Aclaris Therapeutics, Inc.	ATI-045	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-08 (month) in 1mo ESTIMATED	READOUT A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Inp Phase 2 · Schizophrenia	MPLT MapLight Therapeutics, Inc.	ML-007C-MA BID, ML-007C-MA QD	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-08 (month) in 1mo ESTIMATED	READOUT A Study Investigating Intravenous Human Normal Immunoglobulin 10% in Adults With Phase 3 · Chronic Primary Immune Thrombocytopenia (ITP)	Kedrion S.p.A.	Kedrion IVIG 10%	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-08 (month) in 1mo ESTIMATED	READOUT Aleniglipron Phase 2 Body Composition Study Phase 2 · Obesity, Overweight, or Chronic Weight Management	Gasherbrum Bio, Inc., a wholly own	aleniglipron or placebo	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-08 (month) in 1mo ESTIMATED	READOUT Clinical Study to Investigate the Antihypersensitivity Efficacy of a Novel Denti Phase 3 · Dentin Hypersensitivity	HLN Haleon plc	Stannous fluoride and Potassium nitrate	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-08 (month) in 1mo ESTIMATED	READOUT Efficacy and Safety of a Single Dose of LS301-IT for Fluorescence Intraoperative Phase 2 · Non Small Cell Lung Cancer (NSCLC)	Integro Theranostics	LS301-IT 0.1 mg/kg	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-08 (month) in 1mo ESTIMATED	READOUT A Clinical Study to Evaluate the Effect and Side Effect of a New Artificial Tear Phase 3 · Dry Eye Disease	ABBV AbbVie Inc.	ABBV-444, REFRESH OPTIVE UD	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-08 (month) in 1mo ESTIMATED	READOUT A Trial Evaluating Brelovitug vs Delayed Treatment for the Treatment of Chronic Phase 3 · Chronic Hepatitis D Infection	MIRM Mirum Pharmaceuticals, Inc.	Brelovitug 300 mg, Brelovitug 900 mg, De	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-08 (month) in 1mo ESTIMATED	READOUT Study of VYD2311 for the Prevention of COVID-19 Phase 3 · COVID-19	IVVD Invivyd, Inc.	VYD2311-SD, VYD2311-MD	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-08 (month) in 1mo ESTIMATED	READOUT A Study to Evaluate the Efficacy, Safety, and Tolerability of ASC30 Tablets in P Phase 2 · T2DM (Type 2 Diabetes Mellitus)	Ascletis Pharma (China) Co., Limit	ASC30 tablets	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-08 (month) in 1mo ESTIMATED	READOUT A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagen Phase 2 · Prostate Cancer Patients Treated by Radiotherapy, Prostate Cancer (Adenocarcinoma)	CADL Candel Therapeutics, Inc.	aglatimagene besadenovec + valacyclovir,	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-08 (month) in 1mo ESTIMATED	READOUT Study Evaluating the Efficacy and Safety of Chloroprocaine HCl Ophthalmic Gel 3% Phase 4 · Diabetic Macular Edema (DME), Age-Related Macular Degeneration (AMD)	HROW HARROW, INC.	Chloroprocaine Ophthalmic Gel 3% (IHEEZO	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-08 (month) in 1mo ESTIMATED	READOUT Sciatic Nerve Block With ALX006 in Subjects Undergoing Bunionectomy Phase 2 · Hallux Valgus, Bunionectomy	Rebel Medicine Inc	ALX006 (bupivacaine extended-release inj	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-08 (month) in 1mo ESTIMATED	READOUT Safety and Serum Virus Neutralizing Antibody Responses of VYD2311, a COVID-19 Va Phase 3 · COVID-19	IVVD Invivyd, Inc.	COVID-19 mRNA vaccine, VYD2311	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-08-03 in 1mo ESTIMATED	READOUT A Study to Provide Continued Access to and Assess Long-Term Safety of the Study Phase 3 · Advanced Cancer, Metastatic Cancer	Daiichi Sankyo	T-DXd	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-08-04 in 1mo ESTIMATED	READOUT A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Dire Phase 2 · Multiple Myeloma	Janssen Research & Development, LL	JNJ-68284528, Lenalidomide, Daratumumab,	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-08-04 in 1mo ESTIMATED	READOUT A Study of Guselkumab Administered Subcutaneously in Bio-naive Participants With Phase 4 · Arthritis, Psoriatic	Janssen Research & Development, LL	Guselkumab	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-08-04 in 1mo ESTIMATED	READOUT A Study in People With Idiopathic Pulmonary Fibrosis to Test Whether Pirfenidone Phase 2 · Idiopathic Pulmonary Fibrosis	Boehringer Ingelheim	BI 1015550, Pirfenidone	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-08-05 in 1mo ESTIMATED	READOUT A Phase 2a/b Study of the Efficacy and Safety of Subcutaneous Amlitelimab in Adu Phase 2 · Coeliac Disease, Celiac Disease	SNY Sanofi	Amlitelimab, SIGE, Gluten-free product (	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-08-05 in 1mo ESTIMATED	READOUT A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Stud Phase 2 · Chronic Obstructive Pulmonary Disease	Verona Pharma, Inc., a subsidiary	Ensifentrine 3 mg, Glycopyrrolate 21.25	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-08-06 in 2mo ESTIMATED	READOUT A Study of Apremilast in Pediatric Participants in Children With Mild to Moderat Phase 3 · Plaque Psoriasis	AMGN AMGEN INC	Apremilast	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-08-06 in 2mo ESTIMATED	READOUT A Clinical Study of Efinopegdutide in People With Compensated Cirrhosis Due to S Phase 2 · Non-alcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis	Merck Sharp & Dohme LLC	Efinopegdutide	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-08-07 in 2mo ESTIMATED	READOUT A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizum Phase 3 · Axial Spondyloarthritis, Ankylosing Spondylitis	UCB Biopharma SRL	Bimekizumab	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-08-08 in 2mo ESTIMATED	READOUT A Phase III Control Study of the Safety and Immunogenicity of vYF in Pediatric P Phase 3 · Yellow Fever Immunization	SNY Sanofi	Yellow fever vaccine (live), Yellow feve	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-08-10 in 2mo ESTIMATED	READOUT A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Pa Phase 3 · NonSegmental Vitiligo	INCY INCYTE CORP	Ruxolitinib Cream, Vehicle Cream	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-08-11 in 2mo ESTIMATED	READOUT AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2 Phase 2 · Gastric Cancer, Gastroesophageal Junction Cancer	AZN ASTRAZENECA PLC	AZD0901, 5-Fluorouracil, Leucovorin, l-l	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-08-12 in 2mo ESTIMATED	READOUT ADP-A2M4CD8 Monotherapy and in Combination With Nivolumab in HLA-A2+ Subjects Wi Phase 2 · Ovarian Cancer	USWM CT, LLC	Autologous genetically modified ADP-A2M4	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-08-13 in 2mo ESTIMATED	READOUT A Phase 2, Open-Label, Extension Study to Evaluate Long Term Safety and Clinical Phase 2 · Urticaria Chronic	JSPR Jasper Therapeutics, Inc.	Briquilimab	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-08-13 in 2mo ESTIMATED	READOUT Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity a Phase 2 · Overweight, Type 2 Diabetes	Zealand Pharma	Petrelintide	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-08-14 in 2mo ESTIMATED	READOUT Endoscopic Evidence of Maintenance of Healing With Oral NEXIUM in Patients 1 to Phase 3 · Erosive Esophagitis	AZN ASTRAZENECA PLC	Nexium 20mg, Nexium 10mg	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-08-14 in 2mo ESTIMATED	READOUT Effect of Amnio-Maxx on the Healing Rate of Chronic Diabetic Foot Ulcers. Phase 4 · Diabetic Foot Ulcer (DFU), Amnio-Maxx	Royal Biologics	Amnio-Maxx® Dual Layer Amnion Patch	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-08-15 in 2mo ESTIMATED	READOUT Fitusiran Prophylaxis in Male Pediatric Subjects Aged 1 to Less Than 12 Years Wi Phase 2/3 · Hemophilia	Genzyme, a Sanofi Company	Fitusiran	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-08-15 in 2mo ESTIMATED	READOUT The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP5 Phase 1/2 · Advanced Solid Tumor, Advanced Malignant Neoplasm	PMVP PMV Pharmaceuticals, Inc.	rezatapopt, pembrolizumab	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-08-17 in 2mo ESTIMATED	READOUT Safety, Tolerability, and Pharmacokinetics of Exidavnemab in Patients With Parki Phase 2 · Parkinson Disease, Multiple System Atrophy	BioArctic AB	exidavnemab	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-08-18 in 2mo ESTIMATED	READOUT A Study of Raludotatug Deruxtecan (R-DXd) in People With Gastrointestinal Cancer Phase 2 · Gastrointestinal Cancer	Merck Sharp & Dohme LLC	Raludotatug Deruxtecan (R-DXd)	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-08-19 in 2mo ESTIMATED	READOUT A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination Wi Phase 1/2 · Advanced Solid Tumors	REGN REGENERON PHARMACEUTICALS, I	REGN7075, Cemiplimab, Platinum-based dou	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-08-19 in 2mo ESTIMATED	READOUT Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Ch Phase 3 · Carcinoma, Non-Small-Cell Lung	Merck Sharp & Dohme LLC	pembrolizumab/vibostolimab, durvalumab,	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-08-19 in 2mo ESTIMATED	READOUT A Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Phase 3 · Sjogren's Syndrome	AMGN AMGEN INC	Dazodalibep	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change